# Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

> **NCT06150924** · PHASE2 · COMPLETED · sponsor: **Mineralys Therapeutics Inc.** · enrollment: 60 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
- **DRUG:** Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

## Key facts

- **NCT ID:** NCT06150924
- **Lead sponsor:** Mineralys Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-14
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-04-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150924, "Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06150924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*